1. Home
  2. WVE vs APLS Comparison

WVE vs APLS Comparison

Compare WVE & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$15.74

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$25.78

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
APLS
Founded
2012
2009
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
WVE
APLS
Price
$15.74
$25.78
Analyst Decision
Strong Buy
Buy
Analyst Count
16
20
Target Price
$29.94
$33.89
AVG Volume (30 Days)
13.7M
2.4M
Earning Date
11-10-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.36
Revenue
$109,230,000.00
$1,016,397,000.00
Revenue This Year
N/A
$28.88
Revenue Next Year
$16.00
N/A
P/E Ratio
N/A
$72.21
Revenue Growth
103.75
42.11
52 Week Low
$5.28
$16.10
52 Week High
$21.73
$35.57

Technical Indicators

Market Signals
Indicator
WVE
APLS
Relative Strength Index (RSI) 55.08 64.08
Support Level $15.23 $24.56
Resistance Level $18.50 $25.77
Average True Range (ATR) 1.18 1.01
MACD -0.34 0.02
Stochastic Oscillator 16.51 79.42

Price Performance

Historical Comparison
WVE
APLS

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Share on Social Networks: